PsychosisNCT01907282
Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis
A study testing Family Focused Treatment and Enhanced Care in people with Psychosis, run by University of California, Los Angeles at 8 sites in 2 countries.
Trial summary
Preventing psychotic disorders such as schizophrenia and associated functional disability could relieve an enormous burden of personal and family suffering and economic losses to society. Read more about this study
- Who is it for?
- Ages 12 to 35 years
- Conditions the study is for
- Psychosis
- What is being tested?
- Family Focused Treatment and Enhanced Care
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 129 participants
- Where
- 8 sitesin 2 countries
- Study dates
- Jan 2010to Jan 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 35 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Age between 12 years, 0 months and 35 years, 11 months
- Speaks and writes English
- Availability of at least one family member for treatment
- Meets criteria for one of three prodromal syndromes as assessed by the
- Structured Interview for Prodromal Syndromes:
- attenuated positive symptoms that are sub-psychotic in duration and intensity and have begun or worsened in the past year;
- brief intermittent psychosis, defined as or syndromal psychotic symptoms that are have been present intermittently with onset in the previous 3 months; or
- genetic risk and deterioration, defined as a diagnosis of schizotypal personality disorder or having a first degree relative with a psychotic disorder, plus having experienced a substantial decline (30% or greater) in Global Assessment of Functioning scores in the last year.
Who cannot join
- Diagnosis of schizophrenia or schizoaffective disorder
- Pervasive developmental disorders
- Current substance or alcohol dependence
- Neurological disorders
Trial locations and contacts
8 sites in 2 countries.
8 sites in 2 countries
United States7 sites
Emory University
Atlanta, Georgia, 30322
Harvard University/Beth Israel Deconess Medical Center
Boston, Massachusetts, 02215
University of North Carolina
Chapel Hill, North Carolina, 27599
UCLA School of Medicine
Los Angeles, California, 90025
Yale University
New Haven, Connecticut, 06519
Zucker Hillside Hospital
New York, New York, 11004
University of California, San Diego
San Diego, California, 92093
About this study
Preventing psychotic disorders such as schizophrenia and associated functional disability could relieve an enormous burden of personal and family suffering and economic losses to society. This project aims to conduct a pilot randomized trial to determine the efficacy of a family-focused treatment in comparison with treatment-as-usual in enhancing functional outcomes, stabilizing symptoms, and preventing or delaying the onset of full psychosis in transitional age youth with prodromal symptoms. The results of this study will be crucial for the development of cost-effective, evidence-based psychosocial approaches to psychosis prevention and thus will have major implications for public health.
Read the detailed description
The goal of this research is to conduct a multisite randomized trial to determine the efficacy of a 6-month Family-Focused Treatment (FFT) in comparison with Enhanced Care (EC), a treatment-as-usual intervention, in reducing symptoms, enhancing functional outcomes, and preventing or delaying the onset of full psychosis in youth aged 12-35 years who meet criteria for a prodromal risk syndrome according to the Structured Interview for Prodromal Syndromes (SIPS). Our primary, secondary, and tertiary hypotheses, respectively, are that at-risk probands will respond better to FFT than EC at 6- and 12-month follow-ups, in terms of symptom trajectories (SIPS scores), social/family functioning, and first onset of full psychosis. Subjects will be drawn from the participants in a prospective, longitudinal study elucidating predictors and mechanisms of conversion to psychosis (North American Prodrome Longitudinal Study, or NAPLS), on which the sites collaborate. Subjects will be interviewed every 6 months for 1 year to assess positive and negative symptoms, academic and social functioning, family functioning, and conversion to psychosis.
Recent progress in risk ascertainment methodology has enabled reliable identification of persons with prodromal or "clinical high-risk" syndromes, 35% of whom develop psychosis within 2 and ½ years. This paradigm provides an opportunity for developing and testing interventions in the prodromal phase, before the onset of full psychosis and accumulation of substantial functional disability. Psychosocial interventions appear to be well suited to address issues of motivational deficits and functional disability in the psychosis prodrome. Given our present state of knowledge regarding the mechanisms of psychosis onset, and given that initial studies of antipsychotic drugs in prodromal patients have produced discouraging results in terms of prevention, a short term reduction in symptom severity and functional disability may represent a more achievable target than a reduction in psychosis incidence. We have developed and piloted a version of FFT for clinical high risk youth (FFT-CHR) consisting of psychoeducation, communication training, and problem-solving skills training. In randomized trials, adults and adolescents with bipolar disorder and children at-risk for bipolar disorder undergoing FFT improved symptomatically and functionally compared to patients in brief psychoeducational control conditions. Further, an open trial of family psychoeducation for youth at risk for psychosis demonstrated symptomatic and functional improvements relative to baseline scores. However, no randomized controlled study has examined the efficacy of FFT for reducing symptoms or functional disability in youth at risk for psychosis.
In view of the improvements in quality of life and the reductions in costs of care that have occurred with preventive approaches to cardiovascular disease, diabetes, and certain forms of cancer, the field of psychiatry is in need of a major commitment to an early detection/prevention framework for its most debilitating syndromes - the psychotic disorders. The prodromal risk syndrome criteria have resulted in clinical algorithms that are highly effective in predicting onset of full psychosis. However, such knowledge will be of limited utility if we lack the means of intervening in the pre-onset phase in a way that either reduces the likelihood of progression to full psychosis, the accumulation of functional disability, or both. There are currently no cost-effective, evidence-based psychosocial approaches to psychosis prevention. Preventing the neurotoxic effects of early episodes, before these illnesses become chronic, and minimizing the psychosocial sequelae of early episodes, may do much to prevent the long-term disability caused by psychosis and thereby have a major impact on public health. Our study will take the critical next step by performing an initial efficacy test of a highly promising family-focused intervention designed to stabilize symptoms and improve social and role functioning in at risk youth.
- Conditions
- Psychosis
- Being tested
- Family Focused Treatment, Enhanced Care
- Keywords
- Schizophrenia, psychosis
- Medical subject headings
- Psychotic Disorders, Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Family Focused TreatmentBehavioural
Also called Family Therapy, Family Psychoeducation, Behavioral Family Therapy
Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
Enhanced CareBehavioural
Also called Brief psychoeducation
This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
| Study group | Role | What they receive |
|---|---|---|
| Family Focused Treatment | Experimental | Family-Focused Treatment (FFT) consists of 18 sessions of psychoeducation, communication enhancement training, and problem-solving skills training in six months Receives: Behavioral: Family Focused Treatment |
| Enhanced Care | Active comparator | Enhanced care is a 3-session family psychoeducational therapy focused on prevention of psychotic symptoms Receives: Behavioral: Enhanced Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in subthreshold psychotic (positive and negative) symptoms
Participants are rated for the 3 months prior to random assignment and again at 6 and 12 months on the Structured Interview for Prodromal Symptoms (SIPS), from which attenuated psychotic (positive and negative) symptoms are rated.
Measured: Change from pretreatment (assessed for the 3 months prior to randomization) to 12 month reassessment
Secondary outcomes (2)
Conversion to psychosis
Using the Structured Interview for Prodromal Symptoms, we assess whether the participant has converted from a subthreshold state (assessed for the 12 months prior to random assignment) to a fully syndromal psychotic state during the 12 month prospective assessment period.
Measured: Onset of a fully syndromal period of psychosis during the 12 month study
Changes in psychosocial Functioning
Rating scales of global functioning (1-100 scale) and 10-point ratings of social functioning and role (e.g., academic, work) functioning
Measured: Change from pretreatment (1 month prior to randomization) to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2013 (estimated)
- Study startJan 2010
- Primary completionJan 2013
- Study completionJan 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for PsychosisStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 129 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Responsible party
- Principal investigator, David J. Miklowitz, Ph.D., University of California, Los Angeles
- Investigators
- David J Miklowitz, PhD, Principal investigator, UCLA Semel InstituteTyrone Cannon, Ph.D., Study director, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01907282
- Sponsor's protocol ID
- 1RC1MH088546-0110
- Other IDs
- 1RC1MH088546
- Status last verified
- Jul 2013
- First submitted
- 16 Jul 2013
- Last updated
- 24 Jul 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Schlosser DA, Miklowitz DJ, O'Brien MP, De Silva SD, Zinberg JL, Cannon TD. A randomized trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Interv Psychiatry. 2012 Aug;6(3):283-91. doi: 10.1111/j.1751-7893.2011.00317.x. Epub 2011 Dec 20.
PubMed 22182667Miklowitz DJ, O'Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C, Domingues I, Walsh BC, Zinberg JL, De Silva SD, Friedman-Yakoobian M, Cannon TD. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry. 2014 Aug;53(8):848-58. doi: 10.1016/j.jaac.2014.04.020. Epub 2014 Jun 2.
PubMed 25062592
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis
- ClinicalTrials.gov ID
- NCT01907282
- Acronym / sponsor ID
- 1RC1MH088546-0110
- Conditions
- Psychosis
- Keywords
- Schizophrenia, psychosis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 129 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Study start
- Jan 2010
- Primary completion
- Jan 2013 (actual)
- Study completion
- Jan 2013 (actual)
- First posted
- 24 Jul 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Preventing psychotic disorders such as schizophrenia and associated functional disability could relieve an enormous burden of personal and family suffering and economic losses to society. This project aims to conduct a pilot randomized trial to determine the efficacy of a family-focused treatment in comparison with treatment-as-usual in enhancing functional outcomes, stabilizing symptoms, and preventing or delaying the onset of full psychosis in transitional age youth with prodromal symptoms. The results of this study will be crucial for the development of cost-effective, evidence-based psychosocial approaches to psychosis prevention and thus will have major implications for public health.
Detailed description
The goal of this research is to conduct a multisite randomized trial to determine the efficacy of a 6-month Family-Focused Treatment (FFT) in comparison with Enhanced Care (EC), a treatment-as-usual intervention, in reducing symptoms, enhancing functional outcomes, and preventing or delaying the onset of full psychosis in youth aged 12-35 years who meet criteria for a prodromal risk syndrome according to the Structured Interview for Prodromal Syndromes (SIPS). Our primary, secondary, and tertiary hypotheses, respectively, are that at-risk probands will respond better to FFT than EC at 6- and 12-month follow-ups, in terms of symptom trajectories (SIPS scores), social/family functioning, and first onset of full psychosis. Subjects will be drawn from the participants in a prospective, longitudinal study elucidating predictors and mechanisms of conversion to psychosis (North American Prodrome Longitudinal Study, or NAPLS), on which the sites collaborate. Subjects will be interviewed every 6 months for 1 year to assess positive and negative symptoms, academic and social functioning, family functioning, and conversion to psychosis.
Recent progress in risk ascertainment methodology has enabled reliable identification of persons with prodromal or "clinical high-risk" syndromes, 35% of whom develop psychosis within 2 and ½ years. This paradigm provides an opportunity for developing and testing interventions in the prodromal phase, before the onset of full psychosis and accumulation of substantial functional disability. Psychosocial interventions appear to be well suited to address issues of motivational deficits and functional disability in the psychosis prodrome. Given our present state of knowledge regarding the mechanisms of psychosis onset, and given that initial studies of antipsychotic drugs in prodromal patients have produced discouraging results in terms of prevention, a short term reduction in symptom severity and functional disability may represent a more achievable target than a reduction in psychosis incidence. We have developed and piloted a version of FFT for clinical high risk youth (FFT-CHR) consisting of psychoeducation, communication training, and problem-solving skills training. In randomized trials, adults and adolescents with bipolar disorder and children at-risk for bipolar disorder undergoing FFT improved symptomatically and functionally compared to patients in brief psychoeducational control conditions. Further, an open trial of family psychoeducation for youth at risk for psychosis demonstrated symptomatic and functional improvements relative to baseline scores. However, no randomized controlled study has examined the efficacy of FFT for reducing symptoms or functional disability in youth at risk for psychosis.
In view of the improvements in quality of life and the reductions in costs of care that have occurred with preventive approaches to cardiovascular disease, diabetes, and certain forms of cancer, the field of psychiatry is in need of a major commitment to an early detection/prevention framework for its most debilitating syndromes - the psychotic disorders. The prodromal risk syndrome criteria have resulted in clinical algorithms that are highly effective in predicting onset of full psychosis. However, such knowledge will be of limited utility if we lack the means of intervening in the pre-onset phase in a way that either reduces the likelihood of progression to full psychosis, the accumulation of functional disability, or both. There are currently no cost-effective, evidence-based psychosocial approaches to psychosis prevention. Preventing the neurotoxic effects of early episodes, before these illnesses become chronic, and minimizing the psychosocial sequelae of early episodes, may do much to prevent the long-term disability caused by psychosis and thereby have a major impact on public health. Our study will take the critical next step by performing an initial efficacy test of a highly promising family-focused intervention designed to stabilize symptoms and improve social and role functioning in at risk youth.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Family Focused Treatment | Experimental | Behavioral: Family Focused TreatmentFamily-Focused Treatment (FFT) consists of 18 sessions of psychoeducation, communication enhancement training, and problem-solving skills training in six months |
| Enhanced Care | Active comparator | Behavioral: Enhanced CareEnhanced care is a 3-session family psychoeducational therapy focused on prevention of psychotic symptoms |
Who may qualify
- Ages
- 12 to 35 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (8 listed)
- Age between 12 years, 0 months and 35 years, 11 months
- Speaks and writes English
- Availability of at least one family member for treatment
- Meets criteria for one of three prodromal syndromes as assessed by the
- attenuated positive symptoms that are sub-psychotic in duration and intensity and have begun or worsened in the past year;
Key exclusion criteria (4 listed)
- Diagnosis of schizophrenia or schizoaffective disorder
- Pervasive developmental disorders
- Current substance or alcohol dependence
- Neurological disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Family Focused TreatmentAlso: Family Therapy, Family Psychoeducation, Behavioral Family TherapyTreatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving | Behavioural | Family Focused Treatment |
| Enhanced CareAlso: Brief psychoeducationThis 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes. | Behavioural | Enhanced Care |
Primary outcome
Change in subthreshold psychotic (positive and negative) symptoms
Time frame: Change from pretreatment (assessed for the 3 months prior to randomization) to 12 month reassessment
Participants are rated for the 3 months prior to random assignment and again at 6 and 12 months on the Structured Interview for Prodromal Symptoms (SIPS), from which attenuated psychotic (positive and negative) symptoms are rated.
2 secondary outcomes
Conversion to psychosis
Time frame: Onset of a fully syndromal period of psychosis during the 12 month study
Changes in psychosocial Functioning
Time frame: Change from pretreatment (1 month prior to randomization) to 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2013.
- Background: PubMed 22182667Schlosser DA, Miklowitz DJ, O'Brien MP, De Silva SD, Zinberg JL, Cannon TD. A randomized trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Interv Psychiatry. 2012 Aug;6(3):283-91. doi: 10.1111/j.1751-7893.2011.00317.x. Epub 2011 Dec 20.
- Derived from this study: PubMed 25062592Miklowitz DJ, O'Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C, Domingues I, Walsh BC, Zinberg JL, De Silva SD, Friedman-Yakoobian M, Cannon TD. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry. 2014 Aug;53(8):848-58. doi: 10.1016/j.jaac.2014.04.020. Epub 2014 Jun 2.
Related trials for Psychosis
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
RecruitingPhase 2/3
ACP-204 in Adults With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David J Miklowitz, PhD principal investigator
UCLA Semel Institute
Tyrone Cannon, Ph.D. study director
Yale University
8 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Family Focused Treatment and Enhanced Care in people with Psychosis, run by University of California, Los Angeles at 8 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jul 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in subthreshold psychotic (positive and negative) symptoms (time frame: Change from pretreatment (assessed for the 3 months prior to randomization) to 12 month reassessment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01907282, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2013.